| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0959-8049(97)00088-9 |
| P698 | PubMed publication ID | 9301445 |
| P2093 | author name string | L Collette | |
| H Bleiberg | |||
| T Sahmoud | |||
| F Gay | |||
| M Namer | |||
| T Conroy | |||
| L Bedenne | |||
| G Blijham | |||
| B Paillot | |||
| P De Besi | |||
| A J Lacave | |||
| J H Jacob | |||
| P2860 | cites work | Nonparametric Estimation from Incomplete Observations | Q25938997 |
| Thrombogenicity of intravenous 5-fluorouracil alone or in combination with cisplatin | Q28332983 | ||
| Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial | Q29396936 | ||
| 5-Fluorouracil, folinic acid, etoposide and cisplatin chemotherapy for locally advanced or metastatic carcinoma of the oesophagus | Q33492832 | ||
| Cisplatin, 5-fluorouracil, and etoposide for advanced non-small cell lung cancer | Q33494026 | ||
| Combined-modality therapy in the treatment of local-regional esophageal cancer | Q35177643 | ||
| Palliative therapy of inoperable oesophageal carcinoma with radiotherapy and methotrexate: final results of a controlled clinical trial | Q44561658 | ||
| The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer | Q49172589 | ||
| Heparin abolishes the chemotherapy-induced increase in plasma fibrinopeptide A levels | Q50138916 | ||
| Preoperative therapy for esophageal cancer: a randomized comparison of chemotherapy versus radiation therapy | Q67666544 | ||
| Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus | Q68122887 | ||
| Measurements of response to chemotherapy using ultrasound in metastatic liver involvement | Q69510879 | ||
| Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus | Q72683495 | ||
| Cisplatin, fluorouracil, and leucovorin. Increased toxicity without improved response in squamous cell head and neck cancer | Q72689497 | ||
| P433 | issue | 8 | |
| P921 | main subject | fluorouracil | Q238512 |
| cisplatin | Q412415 | ||
| P304 | page(s) | 1216-1220 | |
| P577 | publication date | 1997-07-01 | |
| P1433 | published in | European Journal of Cancer | Q332260 |
| P1476 | title | Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer | |
| P478 | volume | 33 |
| Q50281395 | A Randomized Phase II Study of Leucovorin/5-Fluorouracil with or without Oxaliplatin (LV5FU2 vs. FOLFOX) for Curatively-Resected, Node-Positive Esophageal Squamous Cell Carcinoma. |
| Q85776053 | A phase II study of biweekly paclitaxel and cisplatin chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma: ERCC1 expression predicts response to chemotherapy |
| Q33410922 | A phase II study of paclitaxel and nedaplatin as front-line chemotherapy in Chinese patients with metastatic esophageal squamous cell carcinoma |
| Q44470253 | A phase II trial of docetaxel and CPT-11 in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and gastric cardia |
| Q40085069 | A phase IIa study of rhLTα-Da in combination with cisplatin and fluorouracil for patients with metastatic esophageal squamous cell carcinoma or gastric adenocarcinoma |
| Q35667892 | A pilot study of nimotuzumab combined with cisplatin and 5-FU in patients with advanced esophageal squamous cell carcinoma |
| Q48530079 | A retrospective analysis of 5-fluorouracil plus cisplatin as first-line chemotherapy in the recent treatment strategy for patients with metastatic or recurrent esophageal squamous cell carcinoma |
| Q43750753 | A weekly 24-h infusion of high-dose 5-fluorouracil (5-FU)+leucovorin and bi-weekly cisplatin (CDDP) was active and well tolerated in patients with non-colon digestive carcinomas. |
| Q39978739 | Achalasia combined with esophageal cancer treated by concurrent chemoradiation therapy. |
| Q34635827 | Activity of vinorelbine in gastrointestinal cancers |
| Q42119902 | Anti-EGFR-Targeted Therapy for Esophageal and Gastric Cancers: An Evolving Concept |
| Q57111625 | Apatinib combined with docetaxel as a salvage treatment for metastatic esophageal squamous cancer: a case report |
| Q37701220 | Association between XRCC1 and ERCC1 single-nucleotide polymorphisms and the efficacy of concurrent radiochemotherapy in patients with esophageal squamous cell carcinoma |
| Q33367836 | Bi-weekly chemotherapy of paclitaxel and cisplatin in patients with metastatic or recurrent esophageal cancer |
| Q34204650 | Biweekly docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy for advanced esophageal squamous cell carcinoma: a phase I dose-escalation study |
| Q33426732 | Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study |
| Q36616002 | Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial |
| Q26749536 | Cervical esophageal cancer: a gap in cancer knowledge |
| Q38385570 | Cetuximab in patients with esophageal cancer: a systematic review and meta-analysis of randomized controlled trials. |
| Q24235532 | Chemotherapy for metastatic carcinoma of the esophagus and gastro-esophageal junction |
| Q24244263 | Chemotherapy for metastatic carcinoma of the esophagus and gastro-esophageal junction |
| Q47805138 | Clinical and psychometric validation of an EORTC questionnaire module, the EORTC QLQ-OES18, to assess quality of life in patients with oesophageal cancer |
| Q47104240 | Clinical evaluation of palliative chemoradiotherapy for metastatic esophageal cancer |
| Q55445604 | Clinical results of multimodality therapy for esophageal cancer with distant metastasis. |
| Q33635353 | Current gene expression studies in esophageal carcinoma |
| Q42113341 | Current management of esophageal squamous-cell carcinoma in Japan and other countries |
| Q52581752 | Current therapeutic landscape for advanced gastroesophageal cancers. |
| Q55608156 | DUSP1 enhances the chemoresistance of gallbladder cancer via the modulation of the p38 pathway and DNA damage/repair system. |
| Q90319030 | Detection and management of oligometastatic disease in oesophageal cancer and identification of prognostic factors: A systematic review |
| Q48237143 | Efficacy and safety of recombinant human lymphotoxin-α derivative with cisplatin and fluorouracil in patients with metastatic esophageal squamous cell carcinoma: A randomized, multicenter, open-label, controlled, phase 2b trial |
| Q43194164 | Esophageal cancer chemotherapy: recent advances. |
| Q33702692 | Esophageal cancer in the elderly: an analysis of the factors associated with treatment decisions and outcomes |
| Q64989960 | Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society: part 2. |
| Q64893921 | Evolving Management Strategies for Metastatic Esophageal and Gastroesophageal Junction Adenocarcinoma. |
| Q37347351 | Expression of thymidylate synthase and glutathione-s-transferase pi in patients with esophageal squamous cell carcinoma |
| Q36610452 | First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study |
| Q44715314 | Gemcitabine and cisplatin for patients with metastatic or recurrent esophageal carcinoma: a Southwest Oncology Group Study |
| Q81478073 | High-dose-rate brachytherapy for previously irradiated patients with recurrent esophageal cancer |
| Q59403613 | Incurable Esophageal Cancer: Patterns of Tumor Spread and Therapeutic Consequences |
| Q26822792 | Inhibition of human esophageal squamous cell carcinomas by targeted silencing of tumor enhancer genes: an overview |
| Q38704834 | Irinotecan plus fluorouracil-based regimen as second or third-line chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma |
| Q33557363 | Management of esophageal carcinoma associated with cirrhosis: a retrospective case-control analysis |
| Q41037588 | Neoadjuvant Therapy for Esophageal Adenocarcinoma in the Community Setting-Practice and Outcomes |
| Q36996728 | New and emerging combination therapies for esophageal cancer |
| Q34590804 | New developments in the treatment of esophageal cancer |
| Q36801223 | Nimotuzumab plus paclitaxel and cisplatin as the first line treatment for advanced esophageal squamous cell cancer: A single centre prospective phase II trial |
| Q53071109 | Nomogram to predict treatment outcome of fluoropyrimidine/platinum-based chemotherapy in metastatic esophageal squamous cell carcinoma. |
| Q35571246 | Oesophageal cancer: new developments in systemic therapy |
| Q33341692 | Optimisation of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of hydroxyurea, leucovorin, 5-FU and cisplatin (HLFP regimen) for metastatic oesophageal cancer |
| Q59333000 | Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for stage IV esophageal squamous cell carcinoma: a retrospective controlled study |
| Q37382552 | Paclitaxel plus cisplatin vs. 5-fluorouracil plus cisplatin as first-line treatment for patients with advanced squamous cell esophageal cancer |
| Q47191356 | Palliative chemoradiotherapy versus radiotherapy alone for dysphagia in advanced oesophageal cancer: a multicentre randomised controlled trial (TROG 03.01). |
| Q47402625 | Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer. |
| Q33226028 | Palliative options for esophageal carcinoma |
| Q90679032 | Palliative radiotherapy and chemoradiotherapy in stage IVA/B esophageal cancer patients with dysphagia |
| Q37011966 | Pharmacotherapy for oesophagogastric cancer. |
| Q44058235 | Phase I study of a weekly schedule of a fixed dose of cisplatin and escalating doses of paclitaxel in patients with advanced oesophageal cancer |
| Q36964986 | Phase I trial of oxaliplatin with fluorouracil, folinic acid and concurrent radiotherapy for oesophageal cancer. |
| Q35559881 | Phase I trial of weekly cisplatin, irinotecan and paclitaxel in patients with advanced gastrointestinal cancer |
| Q33434339 | Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal Cancer |
| Q36689140 | Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma |
| Q46965899 | Phase II studies on docetaxel alone every third week, or weekly in combination with gemcitabine in patients with primary locally advanced, metastatic, or recurrent esophageal cancer |
| Q36644156 | Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer |
| Q36614893 | Phase II study of gemcitabine and cisplatin in locally advanced/metastatic oesophageal cancer |
| Q36940910 | Phase II trial of biweekly docetaxel, cisplatin, and 5-fluorouracil chemotherapy for advanced esophageal squamous cell carcinoma |
| Q36609800 | Phase II trial of docetaxel, cisplatin and fluorouracil followed by carboplatin and radiotherapy in locally advanced oesophageal cancer |
| Q37235047 | Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer |
| Q36648325 | Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer |
| Q37142445 | Phase II trial of neoadjuvant chemotherapy with docetaxel, nedaplatin, and S1 for advanced esophageal squamous cell carcinoma |
| Q37269426 | Predictive value of EGFR overexpression and gene amplification on icotinib efficacy in patients with advanced esophageal squamous cell carcinoma |
| Q78250638 | Preoperative chemotherapy for advanced esophageal cancer and relation with histological effect |
| Q36895039 | Pretreatment lymphopenia is an easily detectable predictive and prognostic marker in patients with metastatic esophagus squamous cell carcinoma receiving first-line chemotherapy |
| Q36648089 | Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy |
| Q73670189 | Prospective randomised study of split-course radiotherapy versus cisplatin plus split-course radiotherapy in inoperable squamous cell carcinoma of the oesophagus |
| Q55658098 | Recent advancements in esophageal cancer treatment in Japan. |
| Q92310363 | Safety and Effectiveness of Chemotherapy for Metastatic Esophageal Cancer in a Community Hospital in Brazil |
| Q42287321 | Saudi Oncology Society clinical management guideline series. Esophageal cancer 2014. |
| Q26779217 | State of the art management of metastatic gastroesophageal cancer |
| Q36254407 | The efficacy and toxicities of combined lobaplatin with paclitaxel as a first-line chemotherapy for advanced esophageal squamous cell carcinoma |
| Q84715355 | Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell |
| Q61809538 | Triplet chemotherapy with docetaxel, cisplatin and S-1 for unresectable advanced squamous cell carcinoma of the esophagus: phase I/II trial results |
| Q73470681 | [Non-surgical treatments of esophageal cancers] |
| Q81891664 | [Palliative treatment of esophageal carcinoma: chemotherapy and palliative care] |
Search more.